Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling

dc.contributor.authorBerenjeno, Inma M.
dc.contributor.authorPiñeiro, Roberto
dc.contributor.authorCastillo, Sandra D.
dc.contributor.authorPearce, Wayne
dc.contributor.authorMcGranahan, Nicholas
dc.contributor.authorDewhurst, Sally M.
dc.contributor.authorMeniel, Valerie
dc.contributor.authorBirkbak, Nicolai J.
dc.contributor.authorLau, Evelyn
dc.contributor.authorSansregret, Laurent
dc.contributor.authorMorelli, Daniele
dc.contributor.authorKanu, Nnennaya
dc.contributor.authorSrinivas, Shankar
dc.contributor.authorGraupera i Garcia-Milà, Mariona
dc.contributor.authorParker, Victoria E. R.
dc.contributor.authorMontgomery, Karen G.
dc.contributor.authorMoniz, Larissa S.
dc.contributor.authorScudamore, Cheryl L.
dc.contributor.authorPhillips, Wayne A.
dc.contributor.authorSemple, Robert K.
dc.contributor.authorClarke, Alan
dc.contributor.authorSwanton, Charles
dc.contributor.authorVanhaesebroeck, Bart
dc.date.accessioned2018-07-27T12:26:47Z
dc.date.available2018-07-27T12:26:47Z
dc.date.issued2017-11-24
dc.date.updated2018-07-24T11:55:27Z
dc.description.abstractMutations in PIK3CA are very frequent in cancer and lead to sustained PI3K pathway activation. The impact of acute expression of mutant PIK3CA during early stages of malignancy is unknown. Using a mouse model to activate the Pik3ca(H1047R) hotspot mutation in the heterozygous state from its endogenous locus, we here report that mutant Pik3ca induces centrosome amplification in cultured cells (through a pathway involving AKT, ROCK and CDK2/Cyclin E-nucleophosmin) and in mouse tissues, and increased in vitro cellular tolerance to spontaneous genome doubling. We also present evidence that the majority of PIK3CA(H1047R) mutations in the TCGA breast cancer cohort precede genome doubling. These previously unappreciated roles of PIK3CA mutation show that PI3K signalling can contribute to the generation of irreversible genomic changes in cancer. While this can limit the impact of PI3K-targeted therapies, these findings also open the opportunity for therapeutic approaches aimed at limiting tumour heterogeneity and evolution.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid29170395
dc.identifier.urihttps://hdl.handle.net/2445/124039
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1038/s41467-017-02002-4
dc.relation.ispartofNature Communications, 2017, num. 8
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/317250/EU//VESSEL
dc.relation.urihttp://dx.doi.org/10.1038/s41467-017-02002-4
dc.rightscc by (c) Berenjeno et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer
dc.subject.classificationOncogènesi
dc.subject.otherCancer
dc.subject.otherCarcinogenesis
dc.titleOncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
BerenjenoIM.pdf
Mida:
3.58 MB
Format:
Adobe Portable Document Format